Intensity Therapeutics resumed patient enrollment in Invincible III and Invincible IV, while capital remained the gating factor for Invincible III activation and enrollment speed. Cash and equivalents were $8.5 million as of September 30, 2026.
INTS · Intensity Therapeutics, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, our cash and cash equivalents were approximately $8.5 million. Based on our balances in cash and cash equivalents, our ability to continue our operations is dependent on obtaining additional capital, which is not within our control. As a result, we believe there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Intensity Therapeutics reported enrollment resumed in INVINCIBLE-3 and INVINCIBLE-4 during the third quarter of 2026. Cash and cash equivalents were $8.5 million as of September 30, 2026, while third-quarter net loss was $3.5 million.
Intensity Therapeutics resumed INVINCIBLE-3 enrollment in the third quarter of 2026, while INVINCIBLE-4 data showed 71% pCR versus 42% for SOC. Cash was $8.5 million and nine-month net loss was $9.0 million, raising substantial going-concern doubt.